Koers A1M Pharma AB Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 294 mln. 27,95 mln. 26,13 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -99 mln. -9,42 mln. -8,81 mln. | Nettowinst (verlies) 2025 * | -99 mln. -9,42 mln. -8,81 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 104 mln. 9,89 mln. 9,25 mln. | Nettoliquiditeiten 2025 * | 5 mln. 476K 445K | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-4,33
x | K/w-verhouding 2025 * |
-4,33
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 58,72% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 48 | 01-12-18 | |
Karin Botha
DFI | Director of Finance/CFO | 51 | 14-09-20 |
Michael Reusch
CTO | Chief Tech/Sci/R&D Officer | 64 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Johan Bygge
CHM | Chairman | 68 | 01-05-21 |
Göran Forsberg
BRD | Director/Board Member | 61 | 29-05-19 |
Fredrik Lehmann
BRD | Director/Board Member | 48 | 01-12-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,36% | 52,73 mld. | |
+38,68% | 39 mld. | |
-8,63% | 38,52 mld. | |
+25,46% | 30,38 mld. | |
-11,17% | 26,39 mld. | |
+11,44% | 26,08 mld. | |
+45,09% | 14,15 mld. | |
+32,93% | 12,6 mld. | |
-5,30% | 11,51 mld. |
- Beurs
- Aandelen
- Koers GUARD
- Koers